ClinicalTrials.gg
RecruitingNCT07228091Updated Oct 28, 2026

Surgical Procedure Efficiency Evaluation stuDy

An observational study in Cataract, Vitreous Hemorrhage and Retinal Detachment, sponsored by Alcon Research. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Alcon Research (part of Alcon) · Observational

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 28, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
180
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 116 studies in Cataract by Alcon — 4 open to participants now, 6 under way, none of them phase 3. Cataract · Alcon.

Planned enrollment
5th of 12
180 · median 145
Started
2026
with 4 others
Observational
12 of 116
2 open now
Registered
113th of 116
by date

Among the 116 studies in Cataract by Alcon, this one is the 5th largest by planned enrollment of the 12 observational ones that give a count, is one of 5 that started in 2026, is one of 12 observational ones, and was the 113th registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

4 of the 116 studies in Cataract by Alcon are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 116 studies in Cataract by Alcon, or all of them as a file.
02

Study summary

The purpose of this real-world evidence study is to compare surgical procedure times for UNITY® VCS and CONSTELLATION® Vision System.

Read the detailed description

Eligible subjects will undergo routine scheduled combined anterior-posterior segments surgery (phacovitrectomy). This single visit, time-and-motion study will be conducted in the United Kingdom. This study will be conducted by Alcon Vision LLC.

03

Conditions studied

  • Cataract
  • Vitreous Hemorrhage
  • Retinal Detachment
  • Macular Pucker
  • Macular Holes

Keywords

  • anterior segment ophthalmic surgery
  • posterior segment ophthalmic surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects will be recruited from the clinical practice of the participating Investigator.

Eligibility criteria

Key Inclusion Criteria:

  • Able to understand and sign an form (ICF) that has been approved by an ethics committee.
  • Planned combined phacovitrectomy procedure at one of the selected surgical sites.
  • Planned combined phacovitrectomy procedure with 25-gauge (G) vitrectomy tools.

Key Exclusion Criteria:

  • Unplanned/emergency phacovitrectomy.
  • Pregnant.
  • Past history of phacovitrectomy. cataract, vitrectomy in the planned operative eye.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
180 participants (estimated)
Patient registry
No

Groups and cohorts

  • UNITY VCS

    Subjects will undergo routine scheduled combined anterior-posterior segments surgery (phacovitrectomy)

    Device: UNITY VCS

  • CONSTELLATION

    Subjects will undergo routine scheduled combined anterior-posterior segments surgery (phacovitrectomy)

    Device: CONSTELLATION

Interventions

  • DeviceUNITY VCS

    UNITY® VCS is a CE-marked, FDA-approved ophthalmic microsurgical system that is indicated for both anterior segment (i.e., phacoemulsification and removal of cataracts) and posterior segment (i.e., vitreoretinal) ophthalmic surgery. The focus of this study will be on combined anterior-posterior segments surgery (phacovitrectomy).

    Also known as: UNITY® Vitreoretinal Cataract System (VCS)

  • DeviceCONSTELLATION

    CONSTELLATION is a CE-marked, FDA-approved ophthalmic microsurgical system that is indicated for both anterior segment (i.e., phacoemulsification and removal of cataracts) and posterior segment (i.e., vitreoretinal) ophthalmic surgery. The focus of this study will be on combined anterior-posterior segments surgery (phacovitrectomy).

    Also known as: CONSTELLATION® Vision System

06

What researchers measure

Primary outcomes

  1. Proportion of surgeons replying "efficient" or "very efficient" to the question, "How would you rate overall OR (operating room) efficiency of the console for the combined phaco-vitrectomy surgery (including set-up/tear-down)?

    Responses will be collected on a 5-point scale where 1=Very Inefficient, 2=Inefficient, 3=Neutral, 4=Efficient, and 5=Very Efficient.

    Time frame: Up to Day 1 post completion of the surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.

Of 67 industry-sponsored observational studies under Cataract, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 35. This study's planned 16 months is above that.

Counting every sponsor, half of 235 studies reached it within 16 months; a quarter within 9 and three quarters within 30.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Mar 2027 → Jun 2027 and completion Mar 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2025
First posted
Nov 14, 2025
StartActual
Feb 9, 2026
Primary completionEst.
Jun 2027was Mar 2027
CompletionEst.
Jun 2027was Mar 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 2027→Jun 2027
Oct 28, 2026
Study completion
Mar 2027→Jun 2027
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Primary completion Mar 2027→Jun 2027
    Study completion Mar 2027→Jun 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07228091
Lead sponsor
Alcon Research
Collaborators
Manchester Royal Eye Hospital
Responsible party
Sponsor
First posted
Nov 14, 2025
Start date
Feb 9, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Alcon Call Center
Contact
alcon.medinfo@alcon.com
1-888-451-3937
Manager, Health Economics/Outcomes Research
study director · Alcon Research, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion